PVLA (STOCKS)
Palvella Therapeutics, Inc. Common Stock
$116.510000
+7.700000 (+7.08%)
Prev close: $108.810000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Wesley H. Kaupinen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,674.24M
- Employees
- 14
- P/E (TTM)
- -27.95
- P/B (TTM)
- 7.37
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
15
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.20 | $-0.95 | -0.2492 | -26.21% |
|
Dec 2025 (Q4)
|
$-1.07 | $-0.93 | -0.1413 | -15.20% |
|
Sep 2025 (Q3)
|
$-1.03 | $-0.86 | -0.1749 | -20.45% |
|
Jun 2025 (Q2)
|
$-0.86 | $-0.76 | -0.1044 | -13.82% |
Financial Statements
| Revenues | $2.91M |
| Benefits Costs and Expenses | $52.21M |
| Costs And Expenses | $52.21M |
| Operating Expenses | $45.59M |
| Research and Development | $28.10M |
| Other Operating Expenses | $17.49M |
| Operating Income/Loss | -$45.59M |
| Income/Loss From Continuing Operations After Tax | -$49.30M |
| Income/Loss From Continuing Operations Before Tax | -$49.30M |
| Income Tax Expense/Benefit | $0.00 |
| Interest Income/Expense After Provision For Losses | $2.91M |
| Interest Income/Expense Operating, Net | $2.91M |
| Net Income/Loss | -$49.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$49.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$49.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$4.17 |
| Diluted Earnings Per Share | -$4.17 |
| Basic Average Shares | 35,409,786 |
| Diluted Average Shares | 35,409,786 |
| Assets | $263.76M |
| Current Assets | $263.23M |
| Noncurrent Assets | $528.00K |
| Liabilities | $31.45M |
| Current Liabilities | $9.12M |
| Accounts Payable | $5.44M |
| Wages | $675.00K |
| Other Current Liabilities | $3.00M |
| Noncurrent Liabilities | $22.33M |
| Equity | $232.31M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $232.31M |
| Liabilities And Equity | $263.76M |
| Net Cash Flow From Operating Activities | -$29.10M |
| Net Cash Flow From Operating Activities, Continuing | -$29.10M |
| Net Cash Flow From Investing Activities | -$37.80M |
| Net Cash Flow From Investing Activities, Continuing | -$37.74M |
| Net Cash Flow From Financing Activities | $215.27M |
| Net Cash Flow From Financing Activities, Continuing | $215.27M |
| Exchange Gains/Losses | $37.00K |
| Net Cash Flow | $148.36M |
| Net Cash Flow, Continuing | $148.32M |
| Comprehensive Income/Loss | -$49.09M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$49.20M |
| Other Comprehensive Income/Loss | -$52.85M |